http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0708639-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ebb6a553affdc364c91cffe3baf12564 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 |
| filingDate | 1993-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ca36d47a11e747fc370dd1e4126f914 |
| publicationDate | 1996-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0708639-A1 |
| titleOfInvention | Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine |
| abstract | Methods and compositions are disclosed utilizing the optically pure (+) isomer of sibutramine, which is a potent drug for treatment of depression, Parkinson's disease, cerebral function disorders, obesity, dementia and related disorders, as well as other conditions related to the activity of the compound as an inhibitor of the neuronal reuptake of monoamines. Further, methods and compositions are disclosed utilizing optically pure (+) sibutramine in order to avoid the adverse effects associated with the administration of racemic sibutramine. |
| priorityDate | 1992-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 67.